君實生物(01877.HK)治療輕中度COVID-19臨牀研究達主要研究終點
君實生物(01877.HK)公佈,控股子公司君拓生物與蘇州旺山旺水合作開發的產品口服核(甘)類抗SARS-CoV-2藥物VV116(項目代號:JT001/VV116)用於輕中度新型冠狀病毒肺炎(COVID-19)早期治療的III期註冊臨牀研究達到方案預設的主要終點。公司將於近期與監管部門溝通遞交新藥上市申請。
2021年9月,君拓生物與旺山旺水訂立合作開發合同,共同承擔VV116在合作區域內的臨牀開發和產業化工作。目前,VV116正處於國際多中心的III期臨牀研究階段,多項針對輕中度和中重度COVID-19患者的臨牀研究正在進行中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.